SCHEMBL1886283

SCHEMBL1886283

CCOC(=O)c1scc(-c2ccccc2)c1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.57
ALDH1A1 P00352 8/20 0.57
HPGD P15428 6/20 0.57
HSD17B10 Q99714 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
KDM4E B2RXH2 3/20 0.57
RAB9A P51151 3/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
NPC1 O15118 2/20 0.57
GAA P10253 3/20 0.56
MAPK1 P28482 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
LMNA P02545 4/20 0.55
THRB P10828 1/20 0.55
PRKCZ Q05513 4/20 0.53
GSTO1 P78417 1/20 0.51
CDC7 O00311 1/20 0.50
TRPM8 Q7Z2W7 1/20 0.50
DBF4 Q9UBU7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7848248 0.86 PRKCZ (0.48) MAPTALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL1883906 0.83 ALDH1A1 (0.66) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL1190649 0.81 PRKCZ (0.80) MAPTALDH1A1HPGDHSD17B10MEN1
SCHEMBL689452 0.79 PRKCZ (0.80) MAPTALDH1A1HPGDHSD17B10RAB9A
SCHEMBL3256879 0.79 BCAT2 (0.57) MAPTALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL4265764 0.78 ALDH1A1 (0.63) MAPTALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL189938 0.78 ALDH1A1 (0.49) MAPTALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL31618843 0.78 LMNA (0.62) MAPTALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL31526164 0.78 LMNA (0.62) MAPTALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL6271882 0.77 ALDH1A1 (0.54) MAPTALDH1A1HPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 US disclosed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 WO disclosed
EP-0805812-B1 BICYCLIC SUBSTITUTED HEXAHYDROBENZ(E)ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS ABBOTT LAB (US) 2001-06-13 EP disclosed
US-5792767-A TREATMENT OF BENIGN PROSTATIC HYPERTROPY ABBOTT LABORATORIES (US) 1998-08-11 US disclosed
EP-0805812-A1 BICYCLIC SUBSTITUTED HEXAHYDROBENZ(E)ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS Abbott Laboratories (US) 1997-11-12 EP disclosed
WO-1996022991-A1 BICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS ABBOTT LABORATORIES (US) 1996-08-01 WO disclosed
US-5521181-A Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists ABBOTT LABORATORIES (US) 1996-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof FEN1, UNG, POLH MAPT 4773/4885ALDH1A1 880/4885HPGD 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.